[18F]FPIA PET/CT Imaging in Patients With Solid Tumours
Study Details
Study Description
Brief Summary
The study will be a phase 2, open-label study in patients with solid tumours to explore the relationship between short-chain fatty acid uptake using [18F]FPIA PET/CT and tumour proliferation
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Cancers have increased energy demands to allow for their rapid growth compared to healthy cells. Glucose is the main source of energy for many cells in the body, and clinicians routinely use a scan which looks at glucose metabolism to assess if cancer treatment is working. However, some cancer cells can create energy to survive and grow in a different way, using fatty acids. In this study, the investigators are using a PET/CT scan to look at a variety of cancer types to see which cancers use fatty acids for energy and if this can be measured. The PET/CT scan will be carried out twice on 2 separate visits so that the investigators can check that both scans give the same result.
The investigators will also carry out special tests on the tumour tissue taken during routine cancer surgery. These tests will look for specific substances in the cancer cells that are related to cancer biology and growth. The investigators will then compare the results from the surgical tissue to the results of the scan to see if there is a relationship between them.
The study will look at 21 patients with solid tumours conducted in 4 NCITA accredited centres, which have different strengths in recruiting specific patient/tumour-type cohorts. Each patient will have two scan visits (between 2-15 days apart) prior to any new treatment starting to check that the scan measurements are repeatable.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA) Participants will undergo two PET/CT scans with the tracer [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as [18F]FPIA, on 2 separate visits. |
Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)
[18F]FPIA radiotracer administration
Other Names:
Procedure: PET/CT
PET/CT scan
|
Outcome Measures
Primary Outcome Measures
- The relationship between [18F]FPIA uptake and percent positive tumour cells reported as counts defined per area from whole section immunohistochemistry for PHH3. [6 months]
To explore the relationship between short-chain fatty acid uptake using [18F]FPIA PET/CT and tumour proliferation in patients with solid tumours.
Secondary Outcome Measures
- Estimation of SUVmax of target lesions at 30 minutes and 60 min. [60 min]
The SUVmax of the target lesions will be estimated for both timepoints (i.e. 30 min and 60 min) in order to assess changes in this measurand at the two time points.
- Estimation of tumour-to-background ratio of target lesions at 30 minutes and 60 min. [60 min]
The tumour-to-background ratio of the target lesions will be estimated for both timepoints (i.e. 30 min and 60 min), in order to assess changes in this measurand at the two time points.
- Graphical presentation and reliability of repeat semi-quantitative measure (SUV) of target lesions between two PET scans for each time point (30 min and 60 min). Bland Altman and ICC will be presented. [15 days]
To assess the repeatability of the two [18F]FPIA PET scans, as this can impact the primary end point. The two [18F]FPIA PET scans will be 2-15 days apart, and each will consist of two imaging timepoints (30 minutes and 60 minutes).
- Graphical presentation of [18F]FPIA uptake and whole section immunohistochemistry for Ki-67 and mitotic count (mitoses per mm2) assessed on hematoxylin and eosin (H&E) sections. Pearson's correlation coefficient will be reported. [6 months]
To explore the relationship between [18F]FPIA PET/CT and other known tumour proliferation markers
Other Outcome Measures
- To explore the relationship between [18F]FPIA tumour uptake and histological markers of tumour metabolism. [6 months]
Graphical and tabular description of the relationship of [18F]FPIA uptake with biological markers including pan-mitochondrial markers (succinate dehydrogenase [SDHA], citrate synthase), and fatty acid oxidation enzymes (carnitine palmitoyltransferase I/carnitine acyltransferase I [CPT1/CAT1], carnitine-acylcarnitine translocase [CACT], SLC22A2, SLC22A5, and SLC25A20), evaluated by IHC
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with radiological evidence of solid primary or metastatic target tumour lesions and the following characteristics will be recruited:
-
Age ≥18 years of age
-
Radiologically confirmed tumour size ≥15mm (at least one lesion must be extra-hepatic)
-
The participant is due to undergo surgery within 3 months of the first [18F]FPIA PET/CT
-
There is time to complete the two research PET studies without any delay to surgery
-
WHO performance status 0 -2
-
If female, the participant is either post-menopausal (>1 year), or surgically sterilised (has had a documented bilateral oophorectomy and/or documented hysterectomy, >2 years), or if of childbearing potential, must have a negative urine pregnancy test within 2 hours prior to injection of imaging agent
-
The participant is able and willing to comply with study procedures, and signed and dated informed consent is obtained.
-
eGFR of ≥30 within 3 months of [18F]FPIA injection.
-
The participant is not scheduled to start cancer treatment (e.g. chemotherapy, radiotherapy, biological therapy or immunotherapy) within the study scanning period.
Exclusion Criteria:
-
- The participant has received chemotherapy, immunotherapy, biologic therapy or investigational therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of [18F]FPIA injection or is due neoadjuvant therapy between the PET and surgery.
-
The participant is pregnant or lactating. 3. The participant is scheduled to have a nuclear medicine or contrast scan within 24 hours before the administration of [18F]FPIA.
-
Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Guy's & St. Thomas' NHS Foundation Trust | London | United Kingdom | ||
| 2 | Imperial College Healthcare NHS Trust | London | United Kingdom | ||
| 3 | The Royal Marsden NHS Foundation Trust | London | United Kingdom |
Sponsors and Collaborators
- University College, London
- Cancer Research UK
- Imperial College London
- National Cancer Imaging Translational Accelerator
Investigators
- Principal Investigator: Tara Barwick, University College, London
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 135083